Abstract: Provided are cell based methods to identify memory modulating compounds based on the assessment of KIBRA expression. These methods are also suitable to uncover memory related pathways. The methods comprise the contacting of test compounds with cultured cells and the subsequent assessment of modulation of the KIBRA expression within the cells.

Abstract: The invention relates to various methods of detecting and analyzing protein interactions in a cell, which methods involve the appearance of a specific protein interaction being converted to a permanent detection signal by means of providing, in a manner dependent on said protein interaction, a recombinase activity or protease activity.

Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

Abstract: The present invention relates to a method of treating Amyotrophic Lateral Sclerosis by the targeted delivery of granulocyte-colony stimulating factor to the central nervous system with an adeno-associated virus (AAV) vector.

Abstract: The present invention relates to the use of G-CSF and derivatives thereof for extending the therapeutic window of subsequent thrombolytic treatment of acute stroke, and thereby, allowing the diagnostic examinations which are necessary prior to the thrombolytic treatment in order to avoid hemorrhagic and other severe adverse side effects of the thrombolysis.

Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

Abstract: The invention relates to the use of G-CSF for the treatment of cerebral stroke, particularly cerebral stroke with a large baseline infarct volume. Administration of G-CSF at a total dose of 30 to 180 ?g per kg body weight over a treatment period of about 3 days is suitable for the treatment of stroke. Treatment in accordance with the invention with a total dose of 80 to 150 ?g per kg body weight is preferred.

Abstract: The present invention relates to a method of treating neurological conditions in a mammal by administering a hematopoietic growth factor such as granulocyte-colony stimulating factor (GCSF) and granulocyte-macrophage colony stimulating factor (GMCSF). The invention also provides methods of screening for compounds that bind to a GCSF or GMCSF receptor found on the surface of a neuronal cell; and which provides a neuroprotective, neuroproliferative and/or a STAT gene activation activity.

Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

Abstract: The present invention relates to a screening method for the identification of protective substances which influence haemoglobin formation in neuronal, myocardial and/or skeletomuscular cells, as well as to recombinant constructs, host cells and transgenic animals for the implementation of this method. In addition, the present invention relates to a diagnostic method for the differential diagnosis of neurodegenerative and/or ischaemic diseases in mammals and the use of haemoglobin, a globin or a mutein or fusion protein thereof or a corresponding nucleic acid for the treatment of neurodegenerative and/or ischaemic diseases in mammals. The invention furthermore relates to constructs for gene therapy of such diseases.

Abstract: Described are various methods of detecting and analyzing protein interactions in a cell. The specific protein interaction is detected by a permanent signal generated by a recombinase activity or protease activity that depends on the protein interaction.

Abstract: The present invention relates to a screening method for the identification of protective substances which influence haemoglobin formation in neuronal, myocardial and/or skeletomuscular cells, as well as to recombinant constructs, host cells and transgenic animals for the implementation of this method. In addition, the present invention relates to a diagnostic method for the differential diagnosis of neurodegenerative and/or ischaemic diseases in mammals and the use of haemoglobin, a globin or a mutein or fusion protein thereof or a corresponding nucleic acid for the treatment of neurodegenerative and/or ischaemic diseases in mammals. The invention furthermore relates to constructs for gene therapy of such diseases.

Abstract: The present invention relates to the treatment of amyotrophic lateral sclerosis (ALS) and/or the improvement of motor function in individuals in need of such improvement using a melatonin compound or a pharmaceutical salt of the melatonin compound.

Abstract: The present invention relates to a gene and the coded protein thereof that is involved in the development of sequelae of local ischaemia. The new protein is a serine threonine protein kinase and provides a new therapeutic approach to the prophylaxis and therapy of apoplexy.